Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05789056 · ClinicalTrials.gov registry record · Phase 2
Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome
A Phase 2 study of Netherton Syndrome, sponsored by Quoin Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 4
- Study locations
NCT05789056 is a Phase 2 study of Netherton Syndrome that is actively recruiting participants, run by Quoin Pharmaceuticals. The registered enrollment target is 20 participants, below the 25-participant average among 6 other Netherton Syndrome trials with a reported enrollment target (20% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT05789056, a Phase 2 study of Netherton Syndrome, is actively recruiting participants, sponsored by Quoin Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 4
- Study locations
Study Summary
To assess the safety, tolerability, and efficacy of QRX003 lotion (4%) when added to standard of care treatment regimen, including systemic therapy in subjects with Netherton syndrome
Conditions Studied
Interventions
- DRUG QRX003, 4% Lotion
Study Locations (4)
California
- Site #1 - San Diego
Indiana
- Site #4 - Indianapolis
Massachusetts
- Site #5 - Quincy
Texas
- Site #2 - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-03-14 |
| Est. Completion | 2025-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05789056
The ClinicalTrials.gov registry entry for NCT05789056 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 25-participant average among 6 other Netherton Syndrome trials with a reported enrollment target (20% lower). The listed sponsor is Quoin Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Netherton Syndrome appearing as the primary indexed condition, and to 1 intervention - of which QRX003, 4% Lotion is the first listed.
NCT05789056 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Indiana, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05789056 about?
NCT05789056 is a clinical study titled "Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome". To assess the safety, tolerability, and efficacy of QRX003 lotion (4%) when added to standard of care treatment regimen, including systemic therapy in subjects with Netherton syndrome
What is the current status of trial NCT05789056?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2023-03-14. Estimated completion is 2025-12-30.
What conditions does trial NCT05789056 study?
This clinical trial studies the following conditions: Netherton Syndrome.
What interventions are being tested in trial NCT05789056?
The interventions under investigation include: QRX003, 4% Lotion (DRUG).
Who is sponsoring clinical trial NCT05789056?
This trial is sponsored by Quoin Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05789056 being conducted?
This trial has 4 study locations across California, Indiana, Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Netherton Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome
RECRUITING · Phase 2
-
Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome
ACTIVE NOT RECRUITING · Phase 2
-
The Efficacy and Safety of Secukinumab in Patients With Ichthyoses
COMPLETED · Phase 2
-
Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome
RECRUITING · Phase 1
-
A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725
RECRUITING · Phase 1
-
Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.